SCHEMBL6889140

SCHEMBL6889140

Cn1c(N2CCN(C(=O)O)C(C(C)(C)C)C2)nc2cccnc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
MAPT P10636 2/20 0.43
POLB P06746 1/20 0.43
HSD17B10 Q99714 1/20 0.43
SLC6A7 Q99884 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
TSHR P16473 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
GRM1 Q13255 1/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 3/20 0.38
HTR3E A5X5Y0 2/20 0.38
HTR3B O95264 2/20 0.38
HTR3A P46098 2/20 0.38
HTR3D Q70Z44 2/20 0.38
HTR3C Q8WXA8 2/20 0.38
HTR1A P08908 1/20 0.38
HTR2C P28335 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7845835 0.77 SLC6A7 (0.43) SLC6A7GRM1HTR1ACXCR3
SCHEMBL6971671 0.76 HTR2A (0.45) ALDH1A1MAPTSLC6A7KMT2ATSHR
SCHEMBL4527918 0.74 ADRB2 (0.46) SLC6A7MEN1KMT2AGRM1
SCHEMBL4532377 0.73 HTR3A (0.53) HTR3AHTR2C
SCHEMBL29252729 0.73 AGTR2 (0.48) ALDH1A1SLC6A7MEN1KMT2ATSHR
SCHEMBL7841920 0.72 HRH4 (0.52) SLC6A7HTR2CHRH4
SCHEMBL21224830 0.71 SLC6A7 (0.40) MAPTSLC6A7TSHRGRM1KDM4E
SCHEMBL5549046 0.71 KDM4E (0.35) ALDH1A1MAPTSLC6A7KMT2AKDM4E
SCHEMBL27128220 0.70 GRM1 (0.52) ALDH1A1HSD17B10GRM1KDM4EHTR1A
SCHEMBL2244026 0.70 HTR3E (0.61) ALDH1A1MAPTHSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6821967-B2 AMINES SUCH AS 9-(4-(4-(BENZOTHIAZOL-2-YL)-PIPERAZIN-1-YL)-BUTYL)-9H-FLUORENE-9-CARBOXYLIC ACID (2,2,2-TRIFLUOROETHYL) AMIDE, USED AS MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN ANTAGONISTS, TO PREVENT ATHEROSCLEROSIS OR HYPERLIPEMIA BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-11-23 US disclosed
US-20030166637-A1 Substituted piperazine derivatives, the preparation thereofand their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166637-A1 Substituted piperazine derivatives, the preparation thereofand their use as medicaments MTTP, CETP, CPT1A ALDH1A1 715/4885MAPT 4265/4885POLB 2668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.